Literature DB >> 16732999

Human herpesvirus 6: a clinical update.

Danielle M Zerr1.   

Abstract

Human herpesvirus 6 (HHV-6) is a member of the Roseolovirus genus of the b-herpesvirus subfamily of human herpesviruses. HHV-6 infects virtually all children during the early years of life and, like other herpesviruses, establishes latency after primary infection. In immunocompromised hosts, especially transplant recipients, HHV-6 is able to reactivate and cause disease. There are two subtypes of HHV-6: type A and type B. The two subtypes share certain biological properties and a high level of sequence homology, but differ dramatically in their epidemiology. We have learned much about the epidemiology and clinical impact of HHV-6 in the decades since it was first identified, but many questions still remain. This update focuses on new findings regarding the epidemiology and clinical syndromes of HHV-6, especially as they pertain to primary infection, neurological disease, and the transplant setting. In addition, diagnostics and antiviral treatment are reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16732999

Source DB:  PubMed          Journal:  Herpes        ISSN: 0969-7667


  17 in total

1.  Quantitative HHV-6B antigenemia test for the monitoring of transplant patients.

Authors:  R Loginov; T Karlsson; K Höckerstedt; D Ablashi; I Lautenschlager
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-21       Impact factor: 3.267

Review 2.  [Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture].

Authors:  H Prüss; J Dalmau; V Arolt; K-P Wandinger
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

3.  Inhibitors of nucleotidyltransferase superfamily enzymes suppress herpes simplex virus replication.

Authors:  John E Tavis; Hong Wang; Ann E Tollefson; Baoling Ying; Maria Korom; Xiaohong Cheng; Feng Cao; Katie L Davis; William S M Wold; Lynda A Morrison
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

4.  Insight into the mechanism of human herpesvirus 7 U21-mediated diversion of class I MHC molecules to lysosomes.

Authors:  Nicole L Glosson; Patrick Gonyo; Nathan A May; Christine L Schneider; Laura C Ristow; Qiuhong Wang; Amy W Hudson
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

5.  Evaluation of Epstein-Barr virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.

Authors:  Lotfi Bounaadja; Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-01-16       Impact factor: 5.948

Review 6.  Laboratory and clinical aspects of human herpesvirus 6 infections.

Authors:  Henri Agut; Pascale Bonnafous; Agnès Gautheret-Dejean
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

7.  Human herpesvirus 6 infection impairs Toll-like receptor signaling.

Authors:  Yuichi Murakami; Kazushi Tanimoto; Hiroshi Fujiwara; Jun An; Koichiro Suemori; Toshiki Ochi; Hitoshi Hasegawa; Masaki Yasukawa
Journal:  Virol J       Date:  2010-05-10       Impact factor: 4.099

8.  Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.

Authors:  Francesco Broccolo; Paolo Lusso; Mauro Malnati
Journal:  J Clin Microbiol       Date:  2013-06       Impact factor: 5.948

9.  Reply to "Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays".

Authors:  Lotfi Bounaadja; Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-06       Impact factor: 5.948

10.  Human herpesvirus 6A (HHV-6A) and HHV-6B alter E2F1/Rb pathways and E2F1 localization and cause cell cycle arrest in infected T cells.

Authors:  Guy Mlechkovich; Niza Frenkel
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.